AU2004228008B2 - Tumor-targeting drug-loaded particles - Google Patents

Tumor-targeting drug-loaded particles Download PDF

Info

Publication number: AU2004228008B2
Authority: AU; Australia
Prior art keywords: tumor; microparticles; paclitaxel; therapeutic agent; composition
Prior art date: 2003-04-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2004228008A

Other languages

English (en)

Other versions

AU2004228008A1 (en

Inventor

Jessie L.-S. Au

M. Guillaume Wientjes

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-03

Filing date

2004-04-02

Publication date

2008-11-06

2004-04-02 Application filed by Individual filed Critical Individual

2004-10-21 Publication of AU2004228008A1 publication Critical patent/AU2004228008A1/en

2008-11-06 Application granted granted Critical

2008-11-06 Publication of AU2004228008B2 publication Critical patent/AU2004228008B2/en

2009-02-06 Priority to AU2009200463A priority Critical patent/AU2009200463B2/en

2024-04-02 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims description 254
239000003814 drug Substances 0.000 title claims description 244
229940079593 drug Drugs 0.000 title claims description 160
239000002245 particle Substances 0.000 title description 76
239000011859 microparticle Substances 0.000 claims description 229
229930012538 Paclitaxel Natural products 0.000 claims description 226
229960001592 paclitaxel Drugs 0.000 claims description 226
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 226
239000000203 mixture Substances 0.000 claims description 174
239000002105 nanoparticle Substances 0.000 claims description 148
239000003795 chemical substances by application Substances 0.000 claims description 107
108010010803 Gelatin Proteins 0.000 claims description 95
229920000159 gelatin Polymers 0.000 claims description 95
239000008273 gelatin Substances 0.000 claims description 95
235000019322 gelatine Nutrition 0.000 claims description 95
235000011852 gelatine desserts Nutrition 0.000 claims description 95
238000000034 method Methods 0.000 claims description 89
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 88
238000009472 formulation Methods 0.000 claims description 86
229940124597 therapeutic agent Drugs 0.000 claims description 83
210000001519 tissue Anatomy 0.000 claims description 74
230000006907 apoptotic process Effects 0.000 claims description 67
210000003200 peritoneal cavity Anatomy 0.000 claims description 65
238000011282 treatment Methods 0.000 claims description 59
230000001939 inductive effect Effects 0.000 claims description 46
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 34
230000035515 penetration Effects 0.000 claims description 27
230000036760 body temperature Effects 0.000 claims description 24
238000007912 intraperitoneal administration Methods 0.000 claims description 24
230000009477 glass transition Effects 0.000 claims description 23
210000002700 urine Anatomy 0.000 claims description 23
210000003734 kidney Anatomy 0.000 claims description 22
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 18
210000005068 bladder tissue Anatomy 0.000 claims description 17
210000000683 abdominal cavity Anatomy 0.000 claims description 16
238000011068 loading method Methods 0.000 claims description 16
230000014759 maintenance of location Effects 0.000 claims description 15
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 14
239000000227 bioadhesive Substances 0.000 claims description 14
206010061289 metastatic neoplasm Diseases 0.000 claims description 14
230000001965 increasing effect Effects 0.000 claims description 13
239000002246 antineoplastic agent Substances 0.000 claims description 11
229920000656 polylysine Polymers 0.000 claims description 11
206010005003 Bladder cancer Diseases 0.000 claims description 10
201000005112 urinary bladder cancer Diseases 0.000 claims description 10
239000011248 coating agent Substances 0.000 claims description 9
238000000576 coating method Methods 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 9
239000004005 microsphere Substances 0.000 claims description 9
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 8
206010003445 Ascites Diseases 0.000 claims description 8
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
230000001186 cumulative effect Effects 0.000 claims description 8
239000013583 drug formulation Substances 0.000 claims description 8
201000002528 pancreatic cancer Diseases 0.000 claims description 8
208000014794 superficial urinary bladder carcinoma Diseases 0.000 claims description 8
229960004679 doxorubicin Drugs 0.000 claims description 7
238000001990 intravenous administration Methods 0.000 claims description 7
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
229940127089 cytotoxic agent Drugs 0.000 claims description 6
210000002919 epithelial cell Anatomy 0.000 claims description 6
210000004072 lung Anatomy 0.000 claims description 6
102000008946 Fibrinogen Human genes 0.000 claims description 5
108010049003 Fibrinogen Proteins 0.000 claims description 5
229920002125 Sokalan® Polymers 0.000 claims description 5
239000012141 concentrate Substances 0.000 claims description 5
229940012952 fibrinogen Drugs 0.000 claims description 5
150000004676 glycans Chemical class 0.000 claims description 5
210000004324 lymphatic system Anatomy 0.000 claims description 5
229920001282 polysaccharide Polymers 0.000 claims description 5
239000005017 polysaccharide Substances 0.000 claims description 5
208000005615 Interstitial Cystitis Diseases 0.000 claims description 4
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 4
239000001814 pectin Substances 0.000 claims description 4
229920001277 pectin Polymers 0.000 claims description 4
235000010987 pectin Nutrition 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
239000003242 anti bacterial agent Substances 0.000 claims description 3
210000005013 brain tissue Anatomy 0.000 claims description 3
239000006184 cosolvent Substances 0.000 claims description 3
230000036961 partial effect Effects 0.000 claims description 3
230000000149 penetrating effect Effects 0.000 claims description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
229920000053 polysorbate 80 Polymers 0.000 claims description 3
150000003445 sucroses Chemical class 0.000 claims description 3
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
206010020843 Hyperthermia Diseases 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims description 2
229920001213 Polysorbate 20 Polymers 0.000 claims description 2
239000003623 enhancer Substances 0.000 claims description 2
230000036031 hyperthermia Effects 0.000 claims description 2
210000000496 pancreas Anatomy 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
208000029162 bladder disease Diseases 0.000 claims 4
208000026533 urinary bladder disease Diseases 0.000 claims 4
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims 1
206010046543 Urinary incontinence Diseases 0.000 claims 1
238000009825 accumulation Methods 0.000 claims 1
230000003115 biocidal effect Effects 0.000 claims 1
238000001476 gene delivery Methods 0.000 claims 1
238000001802 infusion Methods 0.000 claims 1
238000010253 intravenous injection Methods 0.000 claims 1
208000019206 urinary tract infection Diseases 0.000 claims 1
229930195724 β-lactose Natural products 0.000 claims 1
210000003932 urinary bladder Anatomy 0.000 description 42
210000004027 cell Anatomy 0.000 description 40
201000011510 cancer Diseases 0.000 description 37
238000009826 distribution Methods 0.000 description 22
238000002360 preparation method Methods 0.000 description 22
210000004881 tumor cell Anatomy 0.000 description 22
241001465754 Metazoa Species 0.000 description 20
239000000243 solution Substances 0.000 description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
241000699670 Mus sp. Species 0.000 description 18
230000000694 effects Effects 0.000 description 18
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 18
241000282472 Canis lupus familiaris Species 0.000 description 16
210000002747 omentum Anatomy 0.000 description 14
210000000056 organ Anatomy 0.000 description 14
210000000188 diaphragm Anatomy 0.000 description 13
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 12
230000008901 benefit Effects 0.000 description 12
229920000642 polymer Polymers 0.000 description 12
230000008685 targeting Effects 0.000 description 12
230000001926 lymphatic effect Effects 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
210000000713 mesentery Anatomy 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
230000000717 retained effect Effects 0.000 description 9
DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 8
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 8
238000004132 cross linking Methods 0.000 description 8
230000004807 localization Effects 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
210000001015 abdomen Anatomy 0.000 description 7
-1 antibodies Proteins 0.000 description 7
239000008280 blood Substances 0.000 description 7
231100000135 cytotoxicity Toxicity 0.000 description 7
230000003013 cytotoxicity Effects 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
229960004857 mitomycin Drugs 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
230000037452 priming Effects 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
230000004044 response Effects 0.000 description 7
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
206010061535 Ovarian neoplasm Diseases 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
201000010099 disease Diseases 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
238000002513 implantation Methods 0.000 description 6
230000002611 ovarian Effects 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
210000003741 urothelium Anatomy 0.000 description 6
241000124008 Mammalia Species 0.000 description 5
238000012512 characterization method Methods 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
238000009792 diffusion process Methods 0.000 description 5
230000000857 drug effect Effects 0.000 description 5
230000002708 enhancing effect Effects 0.000 description 5
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000001394 metastastic effect Effects 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
206010033128 Ovarian cancer Diseases 0.000 description 4
239000004372 Polyvinyl alcohol Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
210000003567 ascitic fluid Anatomy 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
229920002521 macromolecule Polymers 0.000 description 4
201000002628 peritoneum cancer Diseases 0.000 description 4
239000008389 polyethoxylated castor oil Substances 0.000 description 4
229920002451 polyvinyl alcohol Polymers 0.000 description 4
210000000813 small intestine Anatomy 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 3
108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
229930192392 Mitomycin Natural products 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 3
VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
206010046555 Urinary retention Diseases 0.000 description 3
230000001594 aberrant effect Effects 0.000 description 3
230000009471 action Effects 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
229940041181 antineoplastic drug Drugs 0.000 description 3
229920002988 biodegradable polymer Polymers 0.000 description 3
239000004621 biodegradable polymer Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000000812 cholinergic antagonist Substances 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
229960003668 docetaxel Drugs 0.000 description 3
238000004945 emulsification Methods 0.000 description 3
229960000855 flavoxate Drugs 0.000 description 3
SPIUTQOUKAMGCX-UHFFFAOYSA-N flavoxate Chemical compound C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 SPIUTQOUKAMGCX-UHFFFAOYSA-N 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
229960004801 imipramine Drugs 0.000 description 3
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000011462 intraperitoneal chemotherapy Methods 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
208000037821 progressive disease Diseases 0.000 description 3
229960000697 propantheline Drugs 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
238000004736 wide-angle X-ray diffraction Methods 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
DBXFAPJCZABTDR-KUEXGRMWSA-N Cephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@@H](O)[C@H](NC(=O)/C(=C\C)/C)c1ccccc1 DBXFAPJCZABTDR-KUEXGRMWSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
241001467552 Mycobacterium bovis BCG Species 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
DBXFAPJCZABTDR-WBYYIXQISA-N cephalomannine Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 DBXFAPJCZABTDR-WBYYIXQISA-N 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
229960003120 clonazepam Drugs 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
229960004281 desmopressin Drugs 0.000 description 2
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 2
CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 2
229960002777 dicycloverine Drugs 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229960005426 doxepin Drugs 0.000 description 2
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000799 fluorescence microscopy Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
229960002074 flutamide Drugs 0.000 description 2
239000012634 fragment Substances 0.000 description 2
229960002870 gabapentin Drugs 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
210000003041 ligament Anatomy 0.000 description 2
210000001365 lymphatic vessel Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
229940035363 muscle relaxants Drugs 0.000 description 2
239000003158 myorelaxant agent Substances 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
229960005434 oxybutynin Drugs 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
210000005084 renal tissue Anatomy 0.000 description 2
238000004626 scanning electron microscopy Methods 0.000 description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
231100000338 sulforhodamine B assay Toxicity 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
231100000057 systemic toxicity Toxicity 0.000 description 2
VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
229960005383 terodiline Drugs 0.000 description 2
UISARWKNNNHPGI-UHFFFAOYSA-N terodiline Chemical compound C=1C=CC=CC=1C(CC(C)NC(C)(C)C)C1=CC=CC=C1 UISARWKNNNHPGI-UHFFFAOYSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
206010044412 transitional cell carcinoma Diseases 0.000 description 2
238000011870 unpaired t-test Methods 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 1
BWNLUIXQIHPUGO-RDTXWAMCSA-N (2r,4r)-4-(dimethylamino)-2-phenyl-2-pyridin-2-ylpentanamide Chemical compound C1([C@](C(N)=O)(C[C@@H](C)N(C)C)C=2N=CC=CC=2)=CC=CC=C1 BWNLUIXQIHPUGO-RDTXWAMCSA-N 0.000 description 1
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 description 1
UJABSZITRMATFL-UHFFFAOYSA-N 2-methyl-5-phenylfuran-3-carbonyl chloride Chemical compound ClC(=O)C1=C(C)OC(C=2C=CC=CC=2)=C1 UJABSZITRMATFL-UHFFFAOYSA-N 0.000 description 1
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
208000037068 Abnormal Karyotype Diseases 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
241001463143 Auca Species 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000007433 Lymphatic Metastasis Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
206010025538 Malignant ascites Diseases 0.000 description 1
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
238000005766 Middleton reaction Methods 0.000 description 1
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
VMXUWOKSQNHOCA-UHFFFAOYSA-N N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UHFFFAOYSA-N 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
BXSVDJUWKSRQMD-ITMJLNKNSA-N O.O.CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c3ccccc3.CN4[C@@H]5CC[C@H]4C[C@H](C5)OC(=O)[C@H](CO)c6ccccc6.OS(=O)(=O)O Chemical compound O.O.CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c3ccccc3.CN4[C@@H]5CC[C@H]4C[C@H](C5)OC(=O)[C@H](CO)c6ccccc6.OS(=O)(=O)O BXSVDJUWKSRQMD-ITMJLNKNSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
229940127315 Potassium Channel Openers Drugs 0.000 description 1
241000288906 Primates Species 0.000 description 1
108010059712 Pronase Proteins 0.000 description 1
QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002385 Sodium hyaluronate Polymers 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
241000906446 Theraps Species 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
206010066901 Treatment failure Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
238000009557 abdominal ultrasonography Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000842 anti-protozoal effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
229960000794 baclofen Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940124748 beta 2 agonist Drugs 0.000 description 1
NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 description 1
229960000910 bethanechol Drugs 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
229940072282 cardura Drugs 0.000 description 1
AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
229960002727 cefotaxime sodium Drugs 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
229940124443 chemopreventive agent Drugs 0.000 description 1
239000012627 chemopreventive agent Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
239000012829 chemotherapy agent Substances 0.000 description 1
238000007813 chromatographic assay Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
QJHCNBWLPSXHBL-UHFFFAOYSA-N cimetidine hydrochloride Chemical compound [H+].[Cl-].N#C/N=C(/NC)NCCSCC=1N=CNC=1C QJHCNBWLPSXHBL-UHFFFAOYSA-N 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
229960001117 clenbuterol Drugs 0.000 description 1
229940047766 co-trimoxazole Drugs 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
239000012043 crude product Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960003843 cyproterone Drugs 0.000 description 1
DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
231100000409 cytocidal Toxicity 0.000 description 1
230000000445 cytocidal effect Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
229960002677 darifenacin Drugs 0.000 description 1
HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960003314 deracoxib Drugs 0.000 description 1
WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
238000004807 desolvation Methods 0.000 description 1
229940076405 detrol Drugs 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940099170 ditropan Drugs 0.000 description 1
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
229960002236 emepronium Drugs 0.000 description 1
JEJBJBKVPOWOQK-UHFFFAOYSA-N emepronium Chemical compound C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 JEJBJBKVPOWOQK-UHFFFAOYSA-N 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
229960001842 estramustine Drugs 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
229960004207 fentanyl citrate Drugs 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
229940093334 flomax Drugs 0.000 description 1
229950007979 flufenisal Drugs 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
230000000762 glandular Effects 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
229960000930 hydroxyzine Drugs 0.000 description 1
229960003210 hyoscyamine Drugs 0.000 description 1
229930005342 hyoscyamine Natural products 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
229960004187 indoprofen Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000011419 induction treatment Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000001788 irregular Effects 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
RYZCWZZJFAKYHX-LLVKDONJSA-N lanperisone Chemical compound C([C@@H](C)C(=O)C=1C=CC(=CC=1)C(F)(F)F)N1CCCC1 RYZCWZZJFAKYHX-LLVKDONJSA-N 0.000 description 1
229950004624 lanperisone Drugs 0.000 description 1
239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
229940080159 levsin Drugs 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
150000002634 lipophilic molecules Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
244000144972 livestock Species 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000003692 lymphatic flow Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
210000005015 mediastinal lymph node Anatomy 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
239000000693 micelle Substances 0.000 description 1
229960005127 montelukast Drugs 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
210000003098 myoblast Anatomy 0.000 description 1
GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
229960000515 nafcillin Drugs 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
229960000564 nitrofurantoin Drugs 0.000 description 1
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
238000010606 normalization Methods 0.000 description 1
229960001158 nortriptyline Drugs 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
229960001699 ofloxacin Drugs 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
229940105606 oxycontin Drugs 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
229940124583 pain medication Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
229940043138 pentosan polysulfate Drugs 0.000 description 1
229940011043 percocet Drugs 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
229960003799 phenazopyridine hydrochloride Drugs 0.000 description 1
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
229960000395 phenylpropanolamine Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229960003510 propiverine Drugs 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
229960003908 pseudoephedrine Drugs 0.000 description 1
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
229940070891 pyridium Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 description 1
DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 1
229940073454 resiniferatoxin Drugs 0.000 description 1
210000000574 retroperitoneal space Anatomy 0.000 description 1
XPYLKZZOBVLVHB-QDKIRNHSSA-N rociverine Chemical compound CCN(CC)CC(C)OC(=O)[C@H]1CCCC[C@]1(O)C1CCCCC1 XPYLKZZOBVLVHB-QDKIRNHSSA-N 0.000 description 1
229960001538 rociverine Drugs 0.000 description 1
CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000001878 scanning electron micrograph Methods 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
229910001961 silver nitrate Inorganic materials 0.000 description 1
229960001516 silver nitrate Drugs 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940010747 sodium hyaluronate Drugs 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
229950002227 stilonium iodide Drugs 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
229960005314 suramin Drugs 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229940106721 tagamet Drugs 0.000 description 1
ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
229960001693 terazosin Drugs 0.000 description 1
229960002494 tetracaine hydrochloride Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
229960004045 tolterodine Drugs 0.000 description 1
OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
RDTKUZXIHMTSJO-UEIGIMKUSA-M triethyl-[2-[4-[(e)-2-phenylethenyl]phenoxy]ethyl]azanium;iodide Chemical compound [I-].C1=CC(OCC[N+](CC)(CC)CC)=CC=C1\C=C\C1=CC=CC=C1 RDTKUZXIHMTSJO-UEIGIMKUSA-M 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
229960001491 trospium Drugs 0.000 description 1
OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
206010046494 urge incontinence Diseases 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
229950008617 vamicamide Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
229940000146 vicodin Drugs 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940108322 zantac Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Optics & Photonics (AREA)
Nanotechnology (AREA)
Physics & Mathematics (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Epoxy Compounds (AREA)

AU2004228008A 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles Ceased AU2004228008B2 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU2009200463A AU2009200463B2 (en)	2003-04-03	2009-02-06	Tumor-Targeting Drug Loaded Particles

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46082703P	2003-04-03	2003-04-03
US60/460,827		2003-04-03
PCT/US2004/010230 WO2004089291A2 (en)	2003-04-03	2004-04-02	Tumor-targeting drug-loaded particles

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2009200463A Division AU2009200463B2 (en)	2003-04-03	2009-02-06	Tumor-Targeting Drug Loaded Particles

Publications (2)

Publication Number	Publication Date
AU2004228008A1 AU2004228008A1 (en)	2004-10-21
AU2004228008B2 true AU2004228008B2 (en)	2008-11-06

Family

ID=33159807

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2004228008A Ceased AU2004228008B2 (en)	2003-04-03	2004-04-02	Tumor-targeting drug-loaded particles

Country Status (8)

Country	Link
EP (1)	EP1608359A4 (de)
JP (1)	JP4927535B2 (de)
KR (1)	KR100849911B1 (de)
CN (2)	CN102697737B (de)
AU (1)	AU2004228008B2 (de)
CA (1)	CA2520475C (de)
IL (1)	IL171185A (de)
WO (1)	WO2004089291A2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007526322A (ja) *	2004-03-02	2007-09-13	マサチューセッツインスティテュートオブテクノロジー	ナノセル薬物送達系
ES2557988T3 (es) *	2005-03-31	2016-02-01	Lidds Ab	Método para tratar enfermedades de próstata basado en el suministro local de principios activos
BRPI0600285C1 (pt) *	2006-01-13	2011-10-11	Brz Biotecnologia Ltda	compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
JP2007277217A (ja) *	2006-03-17	2007-10-25	Fujifilm Corp	薬剤を均一に封入した生分解性マトリックス
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
EP2092942A1 (de) *	2006-11-20	2009-08-26	Lutonix, Inc.	Wirkstofffreisetzende Beschichtungen für medizinische Vorrichtungen
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
EP2074988B1 (de)	2007-12-28	2018-03-14	Industrial Technology Research Institute	Zusammensetzung mit verzögerter Freisetzung und Herstellungsverfahren dafür
US9161943B2 (en)	2007-12-31	2015-10-20	Industrial Technology Research Institute	Sustained release composition and manufacturing method thereof
WO2009116556A1 (ja) *	2008-03-19	2009-09-24	富士フイルム株式会社	注射用医薬組成物
US8613951B2 (en)	2008-06-16	2013-12-24	Bind Therapeutics, Inc.	Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
JP2012501965A (ja)	2008-06-16	2012-01-26	バインドバイオサイエンシズインコーポレイテッド	薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
ES2721850T3 (es)	2008-06-16	2019-08-05	Pfizer	Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
WO2010068866A2 (en)	2008-12-12	2010-06-17	Bind Biosciences	Therapeutic particles suitable for parenteral administration and methods of making and using same
US20100216804A1 (en)	2008-12-15	2010-08-26	Zale Stephen E	Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
US8357401B2 (en)	2009-12-11	2013-01-22	Bind Biosciences, Inc.	Stable formulations for lyophilizing therapeutic particles
ES2780156T3 (es)	2009-12-15	2020-08-24	Pfizer	Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
KR101314579B1 (ko) *	2011-04-07	2013-10-10	광주과학기술원	파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법
JP2013053103A (ja) *	2011-09-05	2013-03-21	Ltt Bio-Pharma Co Ltd	薬物を封入した肝臓集積性ナノ粒子
WO2013124867A1 (en) *	2012-02-21	2013-08-29	Amrita Vishwa Vidyapeetham University	Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
MX356097B (es)	2012-09-17	2018-05-14	Pfizer Inc Star	Proceso para la preparacion de nanoparticulas terapeuticas.
US10143700B2 (en)	2013-02-19	2018-12-04	Amrita Vishwa Vidyapeetham	Nanoparticle formulations for delivering multiple therapeutic agents
ES2640648T3 (es)	2013-09-16	2017-11-03	Astrazeneca Ab	Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso
MA39734B1 (fr)	2014-03-14	2019-07-31	Pfizer	Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation
WO2016111913A1 (en) *	2015-01-05	2016-07-14	Boston Scientific Scimed, Inc.	Biodegradable drug eluting microsphere for the treatment of solid tumors
GB201505527D0 (en)	2015-03-31	2015-05-13	Jmedtech Pte Ltd	Composition
EP3302423B1 (de)	2015-06-04	2022-05-25	Crititech, Inc.	Partikelproduktionssystem und partikelsammelvorrichtung
US20170128424A1 (en) *	2015-11-11	2017-05-11	Qrono, Inc.	Sustained release pharmaceutical compositions and methods of use
BR112018069628A2 (pt)	2016-04-04	2019-02-12	Crititech, Inc.	métodos para tratamento de tumor sólido
CN106075535B (zh) *	2016-06-14	2019-04-02	武汉纺织大学	一种医用敷料及其制备方法
WO2018011040A1 (en) *	2016-07-13	2018-01-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Plga microparticles loaded with a fluoroquinolone for the treatment of respiratory diseases
US10993919B2 (en)	2016-10-04	2021-05-04	University Of Florida Research Foundation, Inc.	Chondroprotective nanoparticles for the treatment of osteoarthritis
CN107049984A (zh) *	2017-03-14	2017-08-18	武汉理工大学	一种载紫杉醇聚乳酸‑羟基乙酸微球的制备方法
KR102024273B1 (ko) *	2017-03-27	2019-11-04	주식회사 피에프디	약물 작용 관리 장치 및 방법
EP3615145B1 (de)	2017-06-09	2024-05-15	Crititech, Inc.	Zusammensetzungen zur verwendung bei der behandlung von epithelzysten durch intracystische injektion antineoplastischer partikeln
WO2018231908A1 (en)	2017-06-14	2018-12-20	Crititech, Inc.	Methods for treating lung disorders
KR20250057947A (ko)	2017-10-03	2025-04-29	크리티테크, 인크.	암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
WO2019071245A1 (en)	2017-10-06	2019-04-11	Foundry Therapeutics, Inc.	IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
SG11202005672PA (en) *	2018-01-05	2020-07-29	Crititech Inc	Treatment of bladder cancer by local administration of taxane particles
WO2019136490A1 (en)	2018-01-08	2019-07-11	Foundry Therapeutics, Inc.	Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
GB201800912D0 (en) *	2018-01-19	2018-03-07	Ucl Business Plc	Compositions for the treatment of a disease of the urinary tract and treatment of a disease involving the intracellular delivery of the particle
EP3793536A1 (de)	2018-05-12	2021-03-24	Foundry Therapeutics, Inc.	Implantierbare polymerdepots zur kontrollierten freisetzung von therapeutika
WO2019231499A1 (en) *	2018-05-31	2019-12-05	Crititech, Inc.	Use of antineoplastic agents to stimulate the immune system for treatment of cancer
US12303619B2 (en)	2018-08-28	2025-05-20	Foundry Therapeutics, Inc.	Polymer implants
WO2020072090A1 (en) *	2018-10-03	2020-04-09	Crititech, Inc.	Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
EP3750523A1 (de) *	2019-06-13	2020-12-16	CAPNOMED GmbH	System zur abgabe eines wirkstoffes
EP3750524A1 (de) *	2019-06-13	2020-12-16	CAPNOMED GmbH	Verzögerte und anhaltende abgabe von antikrebsmitteln
EP3791865A1 (de) *	2019-09-16	2021-03-17	CAPNOMED GmbH	Wirkstoffabgabesystem mit verzögerter abgabe
WO2022075318A1 (ja) *	2020-10-08	2022-04-14	学校法人関西医科大学	がん治療用組成物の有効性を反映する評価マーカー
US20240016774A1 (en) *	2020-10-14	2024-01-18	Foundry Therapeutics, Inc.	Implantable depots for localized, sustained, controlled release of therapeutic agents to treat cancer and related conditions
US20240307220A1 (en) *	2021-03-05	2024-09-19	H. Lee Moffitt Cancer Center And Research Institute Inc.	Combination Therapy to Treat Temperature Sensitive Mutant Tumors
CN115770224B (zh) *	2023-01-17	2023-04-18	中国人民解放军总医院第一医学中心	一种携载紫杉醇药物的丙烯酸微球及其制备方法
CN118649148B (zh) *	2024-05-30	2024-11-01	河南中医药大学第一附属医院	一种黄芪多糖复合纳米颗粒及其制备方法、应用
CN118948780B (zh) *	2024-08-07	2025-07-15	山东序列生物科技有限公司	一种罗西维林冻干制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5399363A (en) *	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
US6495579B1 (en) *	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
US20020164374A1 (en) *	1997-10-29	2002-11-07	John Jackson	Polymeric systems for drug delivery and uses thereof
WO2000061141A2 (en) *	1999-04-09	2000-10-19	Au Jessie L S	Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6287588B1 (en) *	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6444227B1 (en) *	1999-08-05	2002-09-03	Roche Vitamins Inc.	Process for preparing fat soluble beadlets
EP1343478B1 (de) *	2000-12-21	2007-10-10	Alrise Biosystems GmbH	Induziertes phasenübergangs verfahren zur herstellung von hydrophile wirkstoffe enthaltende mikropartikeln
US20020192280A1 (en) *	2001-05-01	2002-12-19	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents

2004
- 2004-04-02 EP EP04758803A patent/EP1608359A4/de not_active Withdrawn
- 2004-04-02 CA CA2520475A patent/CA2520475C/en not_active Expired - Fee Related
- 2004-04-02 KR KR1020057018841A patent/KR100849911B1/ko not_active Expired - Fee Related
- 2004-04-02 CN CN201210204260.1A patent/CN102697737B/zh not_active Expired - Fee Related
- 2004-04-02 WO PCT/US2004/010230 patent/WO2004089291A2/en not_active Ceased
- 2004-04-02 JP JP2006509638A patent/JP4927535B2/ja not_active Expired - Fee Related
- 2004-04-02 AU AU2004228008A patent/AU2004228008B2/en not_active Ceased
- 2004-04-02 CN CN2004800156847A patent/CN1816331B/zh not_active Expired - Fee Related
2005
- 2005-09-29 IL IL171185A patent/IL171185A/en not_active IP Right Cessation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Au, J et al. Cancer Research 58: 2141-2148 (1998) *

Also Published As

Publication number	Publication date
CN1816331A (zh)	2006-08-09
JP4927535B2 (ja)	2012-05-09
JP2006522148A (ja)	2006-09-28
KR20060006911A (ko)	2006-01-20
CN102697737A (zh)	2012-10-03
CN1816331B (zh)	2012-08-08
WO2004089291A3 (en)	2005-04-21
CN102697737B (zh)	2014-03-19
EP1608359A4 (de)	2011-08-17
WO2004089291A2 (en)	2004-10-21
KR100849911B1 (ko)	2008-08-04
CA2520475C (en)	2012-10-09
CA2520475A1 (en)	2004-10-21
IL171185A (en)	2013-07-31
AU2009200463A1 (en)	2009-03-05
AU2004228008A1 (en)	2004-10-21
EP1608359A2 (de)	2005-12-28

Legal Events

Date	Code	Title	Description
2009-03-05	FGA	Letters patent sealed or granted (standard patent)
2018-10-25	MK14	Patent ceased section 143(a) (annual fees not paid) or expired

Publication	Publication Date	Title
AU2004228008B2 (en)	2008-11-06	Tumor-targeting drug-loaded particles
US8043631B2 (en)	2011-10-25	Tumor targeting drug-loaded particles
Wathoni et al.	2020	Enteric-coated strategies in colorectal cancer nanoparticle drug delivery system
Tan et al.	2009	Doxorubicin delivery systems based on chitosan for cancer therapy
Tang et al.	2015	Co-delivery of docetaxel and Poloxamer 235 by PLGA–TPGS nanoparticles for breast cancer treatment
Sahoo et al.	2021	Oral drug delivery of nanomedicine
Liang et al.	2020	Development of rifapentine-loaded PLGA-based nanoparticles: in vitro characterisation and in vivo study in mice
Wu et al.	2016	Genistein-loaded nanoparticles of star-shaped diblock copolymer mannitol-core PLGA–TPGS for the treatment of liver cancer
Cao et al.	2014	Dual drug release from core–shell nanoparticles with distinct release profiles
Guo et al.	2018	Direct site-specific treatment of skin cancer using doxorubicin-loaded nanofibrous membranes
Bhaskaran et al.	2023	Folic acid-chitosan functionalized polymeric nanocarriers to treat colon cancer
Li et al.	2014	Reduction breakable cholesteryl pullulan nanoparticles for targeted hepatocellular carcinoma chemotherapy
JP2014518862A (ja)	2014-08-07	薬物送達用ポリマーナノ粒子
Xu et al.	2017	Polysaccharide-based nanoparticles for co-loading mitoxantrone and verapamil to overcome multidrug resistance in breast tumor
CN112826939A (zh)	2021-05-25	一种腹腔灌注纳米药物及其制备方法与应用
Li et al.	2015	In situ gel-forming dual drug delivery system for synergistic combination therapy of colorectal peritoneal carcinomatosis
WO2021052923A1 (en)	2021-03-25	Active substance delivery system with delayed delivery
Singh et al.	2024	Cubosomes: an emerging and promising drug delivery system for enhancing cancer therapy
Schaefer et al.	2002	Effect of tricaprin on the physical characteristics and in vitro release of etoposide from PLGA microspheres
CN102641245B (zh)	2014-02-26	一种装载难溶性药物的壳聚糖-壳聚糖衍生物纳米球、制备方法及其作为口服制剂的应用
Froiio et al.	2020	Polymer-based nanocontainers for drug delivery
WO2017084522A1 (zh)	2017-05-26	一种新型抗癌药物纳米制剂及其制备方法
CN101181273A (zh)	2008-05-21	壳聚糖-聚天冬氨酸-5氟尿嘧啶纳米粒子的制备方法
Mehrazin et al.	2024	Electrospray doxorubicin‐loaded polycaprolactone‐polyethylene glycol nanospheres/poloxamer‐chitosan thermogel: A promising candidate for clinical applications
Ashique et al.	2023	Role of block copolymers in colon cancer